FDA PMA FDA Class 3 Approved 🇺🇸 United States

System, Hyperthermia, Rf/Microwave (Benign Prostatic Hyperplasia),Thermotherapy

PMA: P950014 · Supplement: S011 · Decision Mar 13, 1998
Classifications
1
FEI Numbers
10
Registration Numbers
10

Basic Information

Device Name
System, Hyperthermia, Rf/Microwave (Benign Prostatic Hyperplasia),Thermotherapy
Trade Name
PRAKTIS
PMA Number
P950014
Supplement Number
S011
Device Class
FDA Class 3
Product Code
MEQ
Generic Name
System, hyperthermia, rf/microwave (benign prostatic hyperplasia),thermotherapy
Medical Specialty
Unknown
Advisory Committee
Gastroenterology, Urology
Decision
Approved
Decision Code
APPR
Decision Date
March 13, 1998
Date Received
December 31, 1997
Supplement Type
Normal 180 Day Track
Supplement Reason
Change Design/Components/Specifications/Material
Expedited Review
N

Advisory Committee Statement

Approval for a new hardware and software configuration of the Prostatron(TM). The device, as modified, will be marketed under the trade name Prostatron(TM) Praktis and is indicated as a non-surgical treatment alternative to transurethral resection of the prostate (TURP) for the treatment of symptomatic benign prostatic hyperplasia (BPH). It is intended that the Prostatron(TM) Praktis deliver a complete thermal therapy treatment during a single treatment session. The Prostatron(TM) Praktis is available with two treatment protocols, each requiring a unique treatment catheter. Protocol 2.0, which uses the standard Prostaprobe (Black) treatment catheter, is indicated for patients with prostatic lengths of 35 to 50 mm. The higher energy Protocol 2.5, which uses the Prostaprobe (Blue) treatment catheter, is indicated for patients with prostatic lengths of 25 to 50 mm in whom the benefits of obstructive improvement outweigh the attendant risks.

Classifications

This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.

Product Code Device Name
MEQ System, Hyperthermia, Rf/Microwave (Benign Prostatic Hyperplasia),Thermotherapy